AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUN 31 min read$HOWL

EVNIN LUKE sold $64K of HOWL (indirect holdings)

EVNIN LUKE sold 139,803 indirectly-held shares of Werewolf Therapeutics, Inc. (HOWL) at an average of $0.46 ($0.42–$0.47) across 3 trades over 2026-06-01 to 2026-06-03 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · EVNIN LUKE
Published Jun 3, 2026, 10:42 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 28, 2026, 3:46 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$HOWL
Bearish
medium confidence
Mentioned
$HOWL
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$HOWLBearishLow
01

Why it matters

A director's modest share sale under a 10b5‑1 plan provides limited new information for traders.

02

Market read

The filing is a routine insider transaction with low trading relevance.

03

What to watch

Potential upcoming clinical data could offset any negative perception from the sale.

Relevance 2/10Novelty 2/10Timing: today

Background

SEC Form 4 filing discloses insider transactions for public companies.

Company-level read

Ticker impact

$HOWLBearishMedium confidence
Context

Director EVNIN LUKE sold ~64K USD of shares via a 10b5-1 plan, reducing his stake to 482,776 shares.

Expected impact

likely slight pressure as the market prices in the insider sell.

Evidence & confidence

Sale amount under $100K and executed under a pre‑arranged plan; limited material impact on share price.

Market effects

Sector

Minimal effect on the biotech sector; insider sales are routine.

Regional

No regional impact.

Global

None.

Counterpoint

What could challenge this read

The sale could be purely liquidity‑driven; investors may ignore it.

Key entities

  • Company
    Werewolf Therapeutics, Inc.

    Biotech company listed on NASDAQ under ticker HOWL.

  • Insider
    EVNIN LUKE

    Director of Werewolf Therapeutics who sold shares.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

HOWL insider trading history →

Related articles

AUG 21
$HOWLHighAI 8/10

Latham & Watkins Advises on Oversubscribed US$150 Million Private Placement in Connection With Werewolf Therapeutics and Ambros Therapeutics’ Reverse Merger Transaction

Werewolf Therapeutics (HOWL) and Ambros Therapeutics agreed to merge in an all-stock deal. The combined company will focus on Ambros' neridronate program for CRPS-1 and trade as AMBX. They secured $150M in private placement from healthcare investors. Latham & Watkins advised on the transaction.

lw.com2 min
AUG 21
$HOWLHighAI 8/10

Werewolf Therapeutics And Ambros Therapeutics Announce Merger; Secure $150M Financing

Werewolf Therapeutics (HOWL) and Ambros Therapeutics announced an all-stock merger, creating a Nasdaq-listed biotech firm focused on neridronate for CRPS-1. The combined company, trading as AMBX, secured $150M in financing. Neridronate has FDA designations and is in Phase 3 trials, with results expected in 2028. The merger values Ambros at $500M and Werewolf at $47.5M, with a planned Q1 2027 close. HOWL shares surged 1431.19% in pre-market trading.

rttnews.com2 min
AUG 21
$HOWLHighAI 8/10

Why is Werewolf Therapeutics stock surging more than 100% today?

Werewolf Therapeutics (HOWL) stock surged 114.1% after announcing an all-stock merger with Ambros Therapeutics, valued at $500M pre-financing. The combined entity will focus on Ambros's lead drug, neridronate, for Complex Regional Pain Syndrome. The deal includes a $150M private placement and is expected to close by Q1 2027. Werewolf also recently sold its technology platforms to Merck KGaA for up to $33M.

investing.com2 min